title: Platelet activation markers in patients with peripheral arterial disease--a prospective comparison of different platelet function tests.
abstract: Peripheral vascular disease (PVD) is an indicator of diffuse atherosclerosis and is associated with a greatly increased incidence of coronary heart and cerebrovascular disease. Although several studies have assessed whether in vivo platelet activation takes place in patients with PVD, no data are available comparing different platelet function tests in this patient population. We have compared prospectively four tests for the measurement of in vivo platelet activation (plasma betaTG, plasma PF4, intraplatelet betaTG and urinary excretion of 11-dehydro-TXB2) and one in vitro platelet function test (ADP-induced platelet aggregation) in 63 well-characterized patients with intermittent claudication and in 18 age- and sex-matched healthy volunteers. No statistically significant difference was found between patients and controls for plasma betaTG (20.0 +/- 11.8 vs. 18.8 +/- 9.0 ng/ml, respectively), plasma PF4 (5.2 +/- 2.9 vs. 6.3 +/- 3.5 ng/ml), betaTG/PF4 ratio (4.0 +/- 2.9 vs. 3.6 +/- 1.8), intraplatelet betaTG (4503 +/- 1482 vs. 4059 +/- 1065 ng/ml), and threshold aggregatory concentration of ADP (1.7 +/- 0.72 vs. 1.45 +/- 0.56 microM). Urinary 11-dehydro-TXB2 was instead significantly higher in the PVD group (55.4 +/- 27.5 vs. 26.7 +/- 7.0 ng/h, p <0.001). Our study shows that urinary 11-dehydro-TXB2 is a more sensitive index of in vivo platelet activation than the measurement of either platelet specific proteins or of in vitro platelet aggregation in patients with PVD.
authors.affiliation: Institute of Internal Medicine and Vascular Medicine, University of Perugia, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Gresele
authors.forename: M
authors.initials: M
authors.lastname: Catalano
authors.forename: C
authors.initials: C
authors.lastname: Giammarresi
authors.forename: R
authors.initials: R
authors.lastname: Volpato
authors.forename: R
authors.initials: R
authors.lastname: Termini
authors.forename: G
authors.initials: G
authors.lastname: Ciabattoni
authors.forename: G G
authors.initials: GG
authors.lastname: Nenci
authors.forename: G
authors.initials: G
authors.lastname: Davì
mesh_terms: D000244:Adenosine Diphosphate / Q000008:administration & dosage / Q000494:pharmacology; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007866:Leg / Q000098:blood supply / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000097:blood* / Q000652:urine; D015539:Platelet Activation / Q000502:physiology*; D010974:Platelet Aggregation / Q000187:drug effects; D010978:Platelet Factor 4 / Q000378:metabolism; D010979:Platelet Function Tests; D011446:Prospective Studies; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000378:metabolism / Q000652:urine; D001620:beta-Thromboglobulin / Q000378:metabolism
chemical_list: D015415:Biomarkers; D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D013929:Thromboxane B2; D000244:Adenosine Diphosphate; C049235:11-dehydro-thromboxane B2